BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 9571394)

  • 1. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
    Wiseman LR; Spencer CM
    Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel: an update of its use in advanced breast cancer.
    Figgitt DP; Wiseman LR
    Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
    Vermorken JB
    Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
    Spencer CM; Faulds D
    Drugs; 1994 Nov; 48(5):794-847. PubMed ID: 7530632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of taxanes in the treatment of breast cancer.
    Capri G; Tarenzi E; Fulfaro F; Gianni L
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The taxoids. Comparative clinical pharmacology and therapeutic potential.
    Eisenhauer EA; Vermorken JB
    Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.
    Pentheroudakis G; Razis E; Athanassiadis A; Pavlidis N; Fountzilas G
    Med Oncol; 2006; 23(2):147-60. PubMed ID: 16720915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.